News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
ExonHit Therapeutics Inc.'s Extraordinary Shareholders’ Meeting on Second Notice
July 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS--(BUSINESS WIRE)--Regulatory News: •Quorum was not reached •RedPath submitted to Highmark an extensive dossier supporting the clinical utility of PathFinderTG®-Pancreatic cancer
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
April 16, 2025
·
2 min read
·
Tristan Manalac
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025
April 10, 2025
·
5 min read
·
Angela Gabriel
Duchenne muscular dystrophy
Committee Recommends EU Trials of Sarepta’s Elevidys Continue, Day After Holds
April 4, 2025
·
2 min read
·
Dan Samorodnitsky
Alzheimer’s disease
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
March 28, 2025
·
2 min read
·
Dan Samorodnitsky
